NEW YORK (360Dx) – T2 Biosystems announced today that it has partnered with Cidara Therapeutics for the commercial placement of T2Dx instruments to support clinical trials for Cidara’s antifungal CD101s.

As part of the deal, an exclusive pricing program is being created to  accelerate enrollment in trials evaluating Cidara's echinocandin antifungal CD101 and increase the number of hospitals that adopt T2 Biosystems' products, including the T2Candida Panel and T2 Bacterial Panel, following clearance from the  US Food and Drug Administration.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.